{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:52:24Z","timestamp":1788997944127,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:09:14Z","timestamp":1746778154000},"page":"1581-1596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-5331","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"Larenas-Linnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Diamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Jesenak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsy Maureen","family":"Navarrete-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Kappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.05.003_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaip.2014.09.004","article-title":"The allergic asthma phenotype","volume":"2","author":"Schatz","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.chest.2024.11.035","article-title":"Promoting prevention and targeting remission of asthma: a European Forum for Research and Education in Allergy and Airway Diseases consensus statement on raising the bar in asthma care","volume":"167","author":"Jesenak","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.05.003_bib4","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jaip.2025.05.003_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00446-2022","article-title":"Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study","volume":"60","author":"Woehlk","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.003_bib6","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.202209-1708OC","article-title":"Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL study): a double-blind randomized controlled trial","volume":"207","author":"Woehlk","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(54)91620-7","article-title":"Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component","volume":"266","author":"Frankland","year":"1954","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.05.003_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107125","article-title":"Allergen immunotherapy for allergic asthma: the future seems bright","volume":"210","author":"Diamant","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","article-title":"Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma","volume":"74","author":"Lommatzsch","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.05.003_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018186","article-title":"Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre","volume":"7","author":"Demarche","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2025.05.003_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(15)00504-4","article-title":"Inhaled corticosteroid dose-response on blood eosinophils in asthma","volume":"4","author":"Lipworth","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.003_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.201512-2452OC","article-title":"A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED","volume":"195","author":"Kuo","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01836-2020","article-title":"Instability of sputum molecular phenotypes in U-BIOPRED severe asthma","volume":"57","author":"Kermani","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.05.003_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.05.003_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5578\/tt.20239919","article-title":"The profile of severe asthmatics: results from a specialized asthma clinic","volume":"71","author":"Celebi","year":"2023","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.jaip.2025.05.003_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.05.003_bib23","article-title":"Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study","volume":"48","author":"Athanazio","year":"2022","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jaip.2025.05.003_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/17476348.2023.2251403","article-title":"How can we improve our use of allergen immunotherapy as a treatment option for asthma and severe asthma?","volume":"17","author":"Larenas-Linnemann","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib19","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2023.05.028","article-title":"Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status","volume":"11","author":"Rupani","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Frossing","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/JAA.S391970","article-title":"A multi-center study of the prevalence and characteristics of eosinophilic phenotype and high IgE levels among Chinese patients with severe asthma","volume":"16","author":"Ko","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/03007995.2023.2174328","article-title":"Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study","volume":"39","author":"Maspero","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2025.05.003_bib26","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.jaip.2021.07.056","article-title":"Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities","volume":"9","author":"Kerkhof","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-2600(16)30187-4","article-title":"Asthma transition from childhood into adulthood","volume":"5","author":"Fuchs","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib28","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.jaip.2021.03.010","article-title":"Preventive effect of allergen immunotherapy on asthma and new sensitizations","volume":"9","author":"Gradman","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0143-2023","article-title":"From treatable traits to GETomics in airway disease: moving towards clinical practice","volume":"33","author":"Papi","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.05.003_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2500\/aap.2016.37.3981","article-title":"American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions","volume":"37","author":"Larenas-Linnemann","year":"2016","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.05.003_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2500\/aap.2020.41.200001","article-title":"Safety of allergen immunotherapy in North America from 2008-2017: lessons learned from the ACAAI\/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy","volume":"41","author":"Bernstein","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.05.003_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anai.2021.03.011","article-title":"Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma","volume":"127","author":"Epstein","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107766","article-title":"Choosing the right biologic treatment for individual patients with severe asthma - lessons learnt from Picasso","volume":"234","author":"Terl","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","article-title":"Immunological mechanisms of tolerance: central, peripheral and the role of T and B cells","volume":"13","author":"Meng","year":"2023","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41577-022-00786-1","article-title":"Allergen immunotherapy: past, present and future","volume":"23","author":"Durham","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2500\/aap.2022.43.220026","article-title":"Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy","volume":"43","author":"Penagos","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.05.003_bib42","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib43","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/eji.201847668","article-title":"Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc\u03b5RI","volume":"48","author":"Maggi","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13005","article-title":"A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut-allergic adolescents","volume":"93","author":"van der Heiden","year":"2021","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib45","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/all.14833","article-title":"Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab","volume":"76","author":"Manohar","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib46","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype","volume":"10","author":"Rabe","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib49","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/all.16001","article-title":"Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy","volume":"79","author":"Wipperman","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib50","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib51","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib53","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12143","article-title":"Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: a real-life multicentre study (BIONIGE)","volume":"12","author":"Contoli","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.anai.2024.06.016","article-title":"The combination of allergen immunotherapy and biologics for inhalant allergies: exploring the synergy","volume":"134","author":"Olivieri","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2025.01.002","article-title":"Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma","author":"Lee","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/02770903.2019.1658204","article-title":"Combination of immunotherapies for severe allergic asthma","volume":"58","author":"Gulsen","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.05.003_bib60","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/rccm.202302-0234ED","article-title":"Can allergen immunotherapy improve antiviral immunity in patients with allergic asthma?","volume":"207","author":"Upham","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.05.003_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.37349\/eaa.2024.00030","article-title":"Allergen-specific immunotherapy for allergic asthma: what\u2019s new?","volume":"2","author":"Asperti","year":"2024","journal-title":"Explor Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib62","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/all.15817","article-title":"Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: an EAACI position paper","volume":"78","author":"Kappen","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib63","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2025.05.003_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib65","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma","volume":"125","author":"Massanari","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/pai.12306","article-title":"Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma","volume":"25","author":"Lambert","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/aei.v50i2.469","article-title":"Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma","volume":"50","author":"Valdesoiro-Navarrete","year":"2022","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.jaip.2025.05.003_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00639-2022","article-title":"Adding a biologic to allergen immunotherapy increases treatment efficacy","volume":"9","author":"Bo\u017cek","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.05.003_bib69","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/02770903.2023.2293057","article-title":"Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma","volume":"61","author":"Bozek","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.05.003_bib70","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/02770903.2024.2368193","article-title":"Efficacy and safety of subcutaneous immunotherapy combined with omalizumab in children with dust mite-induced asthma","volume":"61","author":"Long","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.05.003_bib71","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/alr.23470","article-title":"Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma","volume":"15","author":"Shen","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.05.003_bib72","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.alit.2022.05.010","article-title":"Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis","volume":"71","author":"Hoshino","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.05.003_bib73","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.05.003_bib74","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/vaccines12091046","article-title":"Dupilumab and house dust mite immunotherapy in patients with atopic dermatitis: a preliminary study","volume":"12","author":"Bogacz-Piaseczynska","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaip.2025.05.003_bib75","doi-asserted-by":"crossref","first-page":"682","DOI":"10.4168\/aair.2024.16.6.682","article-title":"Combined dupilumab and allergen-specific immunotherapy in severe refractory atopic dermatitis","volume":"16","author":"Kim","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2025.05.003_bib76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.15586\/aei.v51i2.778","article-title":"Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis","volume":"51","author":"Ding","year":"2023","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaip.2025.05.003_bib77","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.anai.2022.08.014","article-title":"Safety of subcutaneous immunotherapy in patients with severe asthma","volume":"129","author":"Chow","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaip.2023.11.011","article-title":"Anaphylaxis in clinical trials of sublingual immunotherapy tablets","volume":"12","author":"Nolte","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.05.003_bib79","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/all.13208","article-title":"Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.05.003_bib80","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2025.05.003_bib81","doi-asserted-by":"crossref","first-page":"s11","DOI":"10.29262\/ram.v64i0.272","article-title":"Mexican Asthma Guidelines: GUIMA 2017 [article in Spanish]","volume":"64","author":"Larenas-Linnemann","year":"2017","journal-title":"Rev Alerg Mex"},{"key":"10.1016\/j.jaip.2025.05.003_bib84","first-page":"1","article-title":"[MIA 2.0, comprehensive asthma management, guidelines for Mexico]","volume":"82","author":"Larenas-Linnemann","year":"2025","journal-title":"Bol Med Hosp Infant Mex"},{"key":"10.1016\/j.jaip.2025.05.003_bib82","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the Asthma Management Guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.003_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaip.2023.11.031","article-title":"Allergen immunotherapy for asthma","volume":"12","author":"Kappen","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:40:42Z","timestamp":1755650442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825004258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825004258"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.003","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}